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ORIGINAL ARTICLE

Indicators of Cardiac Autonomic Dysfunction
Associated with Chronic Hyperglycemia: Implications
on Vascular Surrogates and Heart Failure
Yap-Hang Chan a,b,*, Bernard M.-Y. Cheung a,b, Hung-Fat Tse a,b,**
a
b

Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China
Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China

Abstract
Background: Limited data exist on the role of chronic hyperglycemia-related cardiac autonomic dysfunction in incident
heart failure (HF). We investigated the relations of resting heart rate (HR) and PR interval with chronic hyperglycemia,
and effects on new-onset HF.
Methods: We prospectively studied 550 patients with prior coronary disease, ischemic stroke and/or type 2 diabetes.
Incident HF was ascertained. Heart rate-PR interval dissociation was deﬁned as counter-physiological co-occurrence of
increased PR interval (>mean; 173.3 ms) and increased resting HR (>mean; 64.4 beats/min).
Results: Over 63 ± 11 months, 6.7% of patients developed new-onset HF. Resting HR ≥ 75bpm was independently
predictive of new-onset HF (HR ¼ 3.35 [95%CI: 1.24e9.04], P ¼ 0.017). Furthermore, baseline HR was associated with
HbA1c (R ¼ 0.11, P ¼ 0.012). At univariable and multivariable analyses, HbA1c remained independently associated with
resting HR ≥ 75 bpm (OR ¼ 1.18, 95%CI [1.00e1.40], P ¼ 0.046). Moreover, the normal inverse relation between PR
interval and resting HR is lost in this group of high-risk cardiac patients (R ¼ ¡0.03, P ¼ 0.46). Heart rate-PR interval
dissociation was signiﬁcantly associated with HbA1c > 7 (28% versus 17%, P ¼ 0.006).
Conclusion: Chronic hyperglycemia is associated with elevated resting HR and counter-physiological dissociation of
HR and PR interval, and that such elevated resting HR is a predictor of new-onset HF in cardiovascular patients with
prevailing diabetes.
Keywords: Cardiac autonomic dysfunction, Resting heart rate, Heart failure, PR interval, Diabetes mellitus

Introduction

D

iabetes mellitus (DM), on top of its wellrecognized causal role in atherosclerotic cardiovascular (CV) diseases, is closely linked to the
development and progression of heart failure (HF)
via multiple pathways. For instance, autonomic
dysfunction as a microvascular complication of
diabetes, is implicated in the pathophysiology of
diabetic cardiomyopathy alongside with a

constellation of abnormalities such as microvascular
and diastolic dysfunction.
Cardiac autonomic dysfunction independently
predicts increased adverse CV events [1] and sudden cardiac death [2]. Moreover, autonomic
dysfunction, such as indicated by depressed heart
rate (HR) variability, also predicts poor physical
performance after cardiac rehabilitation in HF patients [3]. Cardiac autonomic dysfunction is now
considered to be an important therapeutic target for
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HF based on a scientiﬁc statement of the European
Society of Cardiology (2017) [4]. Assessment
methods for cardiac autonomic dysfunction has
been variable. Commonly described parameters
include the time- or frequency-domain measures of
HR variability, HR turbulence and recovery, and the
QT-RR slope [5]. Amongst all, elevation of resting
HR is a simple but cardinal feature of cardiac
autonomic dysfunction [6], and in itself predicts
adverse cardiac outcomes and all-cause mortality.
Nevertheless, there is limited data on how elevation
of resting HR and its relations with glycemic level
impacts on incident HF risk. Also, little is known
regarding how its relation with PR interval, an
electrocardiographic marker of vagal tone, changes
with glycemic level.
We hypothesize that elevation of resting HR that
is linked to chronic glycemic level would negatively
impact on risk of incident HF. We secondarily hypothesized that the normally inverse relation between resting HR and PR interval could be lost in
patients with chronic hyperglycemia, which may
serve as a marker of autonomic dysfunction.

collected for biochemical measurements of serum
creatinine, triglycerides, high-density lipoprotein
(HDL)-cholesterol, low-density lipoprotein (LDL)cholesterol, glucose, HbA1c, and high-sensitivity Creactive protein (hs-CRP).

Methods

Assessment of arterial stiffness

Patient sample

Brachial-ankle pulse wave velocity (PWV) was
non-invasively measured using VP-2000 System
(Colin Corp., USA) [9,10]. Brachial-ankle PWV was
derived as distances between the respective brachial
versus tibial arterial measurement points, divided
by the time used for pulse transit between the systolic R-wave and waveform upstroke at the respective arterial site. System software with R-wave
synchronisation beyond 10 cardiac cycles was used,
with averaging of the left and right-sided derived
estimates. Our centre had good intra-observer
variability for PWV (assessment correlation
coefﬁcient ¼ 0.87, P < 0.001).

We performed an analytical study in a prospective
clinical cohort of 550 consecutive patients with CV
disease or risk equivalent, who were recruited from
internal medicine outpatient clinics of the Hospital
Authority Hong Kong West Cluster during the
period from Sep 2005 to Apr 2008. Of these subjects,
316 (58%) had coronary artery disease, and 125
(23%) had previous stroke. The prevalence of DM,
hypertension, and hyperlipidemia were respectively
51%, 67%, and 66%. Inclusion and exclusion criteria
had prior been detailed [7]. Subjects gave written
informed consent and the cohort study was
coherent with the Declaration of Helsinki, and
approved by the Ethics Committee of the University
of Hong Kong. During the follow-up period from
Dec 2007 to May 2012, occurrences of incident clinical events were retrieved from the medical records
of the Clinical Management System (CMS), the
territory-wide computerized clinical data network.
Primary endpoint of the study was incident HF.
Diagnostic criteria of CV diseases had been prior
described [7].
Baseline clinical and laboratory assessments
Demographic and clinical data was collected at
patient assessment at baseline. Fasting blood was

Carotid intimaemedia thickness (IMT)
Assessment for carotid IMT was performed by
vascular ultrasound, as prior described. Brieﬂy,
measurements of the distance between the lumenintima and media-adventitia of the carotid arterial
wall were made using electronic calipers [8], from
each of the anterior, lateral, and posterior projections of bilateral carotid arteries. Three IMT
measurements were made on the proximal and
distal walls of each of the bilateral common carotid
arteries, carotid bifurcation, and internal carotid
arteries. The mean maximum IMT was calculated
from the maximum IMT values from 12 previously
selected segments in the carotid arteries. Our centre
had good intra-observer variability for IMT measurement (correlation coefﬁcient ¼ 0.97, P < 0.001).

Heart rate-PR interval dissociation
Resting HR was estimated from pulse rate at
standard blood pressure cuff measurement.
Elevated resting HR was generally deﬁned a priori as
HR  75bpm, as increased HR beyond this cut-off
has been shown to be associated with increased risk
of adverse CV outcomes, such as death after
myocardial infarction [11]. Elevated HR beyond this
cut-off has also been shown to impact on effect of
CV therapy, such as beneﬁts of ivabradine in heart
failure patients [12]. Standard 12-lead ECG was
performed. Automated software-derived estimates
were obtained for PR interval and QRS duration.
Here within this sample, HR-PR interval
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dissociation is deﬁned as the counter-physiological
co-occurrence of increased PR interval (>mean
value in this sample; 173.3 ms) and increased resting
HR (>mean value in this sample; 64.4 beats/min
[bpm]), and is proposed as a marker of autonomic
dysregulation.
Statistical analysis
Predictors for incident HF was examined using
the Cox regression analyses. A forward stepwise
multivariable model by cox proportional regression
was used to estimate Hazard Ratios (HR) for incident HF in which each potentially confounding
variable with p-value 0.10 (based on univariable
analysis) was entered. Relations between resting HR
and carotid IMT/PWV were examined using univariable and multivariable linear regression. Analyses were performed using SPSS Statistics (Version
27.0) (see Table 1).

Results
Prediction for incident HF and vascular function
markers
Clinical characteristics of subjects are presented in
Table 1.
Over 63.0 ± 10.9 months of follow-up, 37 patients
(6.7%) developed new-onset HF. Baseline resting
HR was associated with new-onset HF at follow-up
(P < 0.001). C-statistic for prediction of new-onset
HF by resting HR was 0.68 (Figure 1, P < 0.001).
Maximum KeS metric was observed at the cut-off of
71.5bpm, with corresponding sensitivity of 54.1%
and speciﬁcity of 75.4%. Adjusted for potential
confounders, Cox regression analysis showed that
resting HR  75bpm was independently predictive
of new-onset HF (HR ¼ 3.02 [95%CI 1.22 to 7.46],
P ¼ 0.017, Table 2). Sensitivity analyses using the
cut-off of HR > 64.4bpm based on the same multivariable model had yielded similar results

Table 1. Baseline clinical characteristics of study participantsa.

Male [n (%)]
Age (years)
Body mass index (kgm2)
Coronary Artery Disease [n (%)]
Prior stroke [n (%)]
Diabetes mellitus [n (%)]
Hypertension [n (%)]
Hyperlipidemia [n (%)]
Current/Past smoker [n (%)]
Regular Physical activity [n (%)]
Mean resting pulse rate (/min)
Mean systolic blood pressure (mmHg)
Mean diastolic blood pressure (mmHg)
Mean serum LDL-cholesterol (mmol/L)
Mean serum HDL-cholesterol (mmol/L)
Mean serum triglycerides (mmol/L)
Mean serum fasting glucose (mmol/L)
Mean HbA1c (%)
Mean hs-CRP (mg/L)
Mean serum creatinine (mmol/L)
Medications:
ACEI/ARB [n (%)]
Beta-blockers [n (%)]
Calcium channel blockers [n (%)]
Aspirin [n (%)]
Statin [n (%)]
PR interval (ms)
QRS duration (ms)
Mean maximum carotid IMT (mm)
Mean PWV (cm/s)

Resting HR
<75 (n ¼ 439)

Resting HR
75 (n ¼ 111)

p-value

305 (70%)
65.4 ± 11.3
25.3 ± 3.3
265 (60%)
92 (22%)
202 (46%)
278 (64%)
282 (65%)
199 (46%)
140 (32%)
58.9 ± 9.5
138.5 ± 17.8
78.9 ± 9.6
2.60 ± 0.72
1.28 ± 0.34
1.52 ± 1.07
6.19 ± 2.01
6.91 ± 1.42
2.81 ± 9.31
87.6 ± 26.8

71 (64%)
69.3 ± 9.3
25.0 ± 3.3
51 (46%)
33 (31%)
76 (69%)
88 (81%)
70 (67%)
44 (40%)
48 (44%)
86.0 ± 10.5
156.4 ± 21.6
80.5 ± 9.5
2.56 ± 0.74
1.27 ± 0.38
1.57 ± 0.78
6.81 ± 2.31
7.30 ± 1.56
3.91 ± 6.67
102.8 ± 60.6

0.265
<0.001*
0.416
0.006*
0.047*
<0.001*
0.001*
0.674
0.254
0.023*
<0.001*
<0.001*
0.131
0.612
0.835
0.627
0.016*
0.018*
0.310
0.016*

239 (56%)
221 (52%)
108 (25%)
308 (73%)
264 (62%)
173.5 ± 27.4
95.3 ± 28.8
1.01 ± 0.27
1759.0 ± 373.7

70 (66%)
56 (53%)
45 (43%)
68 (64%)
57 (54%)
172.6 ± 29.2
94.8 ± 17.2
1.13 ± 0.35
1952.4 ± 469.1

0.060
0.772
0.001*
0.092
0.123
0.758
0.855
0.002*
0.001*

*P-value<0.05.
a
All values are presented as mean ± SD, except where indicated otherwise. HR, heart rate; HDL, high density lipoprotein; LDL, low
density lipoprotein; HbA1c, glycosylated haemoglobin A1c; hs-CRP, hlrigh-sensitivity C-reactive protein; ACEI, angiotensin-converting
enzyme inhibitors; ARB, angiotensin receptor blockers; IMT, intima-media thickness; PWV, pulse wave velocity.
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(HR ¼ 2.66 [95%CI 1.16 to 6.09, P ¼ 0.020]. Increased
resting HR was associated with increased mean
maximum carotid IMT (R ¼ 0.20, P < 0.001) and
brachial-ankle PWV (R ¼ 0.30, P < 0.001). Nevertheless, these relations were not statistically signiﬁcant after adjustment for potential confounders in
the multivariable model (Tables 3 and 4).
Relation of autonomic dysfunction indices with
glycemic level

Figure 1. Resting HR predicts new-onset HF (C-statistic ¼ 0.68,
P < 0.001). Maximum KeS metric was observed at the cut-off 71.5bpm,
with corresponding sensitivity of 54.1% and speciﬁcity of 75.4%.

Furthermore, baseline resting HR was positively
associated with HbA1c (R ¼ 0.11, P ¼ 0.012). Mean
resting HR was increased in patients with
HbA1c > 7 (66.2 ± 15.0 versus 63.2 ± 14.0 bpm,
P ¼ 0.022). Adjusted for potential confounders (age,
gender, history of coronary artery disease, ischemic
stroke, systolic and diastolic blood pressure, use of
CV medications, physical activity, BMI), HbA1c
remained independently associated with increased
resting HR  75 bpm (OR ¼ 1.18 [95%CI
1.003e1.396], P ¼ 0.046). Moreover, the normal inverse relation between PR interval and resting HR is

Table 2. Predictors for incident heart failurea.
Univariable Modelb

Age (years)
Male
Body mass index (kgm2)
Coronary Artery Disease
Prior stroke
Diabetes mellitus
Current/Past smoker
Regular Physical activity
Systolic BP (mmHg)
Diastolic BP (mmHg)
LDL-cholesterol (mmol/L)
HDL-cholesterol (mmol/L)
Triglycerides (mmol/L)
Fasting glucose (mmol/L)
HbA1c (%)
hs-CRP (mg/L)
Serum creatinine (mmol/L)
Medications:
Beta-blockers
ACEI/ARB
Calcium channel blockers
Aspirin
Statin
Resting heart rate (bpm)
Elevated Heart rate 75bpm

Multivariable Modelc

HR [95% CI]

P-value

HR [95% CI]

P-value

1.19
0.72
1.03
2.67
1.46
0.79
1.51
0.41
1.02
0.98
0.72
0.78
0.99
0.98
0.99
1.05
1.01

[1.13
[0.38
[0.94
[1.27
[0.72
[0.41
[0.78
[0.19
[1.01
[0.95
[0.44
[0.27
[0.70
[0.82
[0.77
[1.01
[1.01

to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to

1.26]
1.40]
1.13]
5.62]
2.93]
1.51]
2.91]
0.91]
1.03]
1.02]
1.19]
2.21]
1.40]
1.16]
1.27]
1.09]
1.02]

<0.001*
0.33
0.57
0.010*
0.29
0.47
0.22
0.029*
0.007*
0.34
0.20
0.64
0.93
0.79
0.95
0.022*
<0.001*

1.19 [1.12 to 1.28]

<0.001*

1.22 [0.36 to 4.07]

0.75

0.32 [0.12 to 0.81]
1.00 [0.98 to 1.02]

0.017*
0.89

1.02 [0.97 to 1.08]
1.00 [0.996 to 1.011]

0.41
0.41

1.61
1.80
1.21
3.09
2.17
1.03
3.11

[0.81
[0.88
[0.60
[1.20
[1.03
[1.01
[1.62

to
to
to
to
to
to
to

3.19]
3.66]
2.42]
7.99]
4.56]
1.05]
5.96]

0.17
0.11
0.59
0.020*
0.041*
0.001*
0.001*

4.5 [1.2 to 16.9]
0.93 [0.31 to 2.80]
1.04 [1.01 to 1.08]
3.02 [1.22 to 7.46]

0.025*
0.90
0.011*
0.017*

Abbreviations: BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, glycosylated haemoglobin A1c;
hs-CRP, high-sensitivity C-reactive protein; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
*P < 0.05.
a
Absolute change estimates and 95% conﬁdence interval of Hazards Ratio (HR) of incident heart failure explained by variable of
interest as estimated by univariable and multivariable Cox proportional hazards regression model.
b
Crude unadjusted model.
c
Adjusted for potential confounders as deﬁned as from univariable analysis with p-value 0.10.
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Table 3. Predictors for mean maximum carotid intima-media thickness (IMT)a.
Univariable Modelb

Age (years)
Male
Body mass index (kgm2)
Coronary Artery Disease
Prior stroke
Diabetes mellitus
Current/Past smoker
Regular Physical activity
Systolic BP (mmHg)
Diastolic BP (mmHg)
LDL-cholesterol (mmol/L)
HDL-cholesterol (mmol/L)
Triglycerides (mmol/L)
Fasting glucose (mmol/L)
HbA1c (%)
hs-CRP (mg/L)
Serum creatinine (mmol/L)
Medications:
Beta-blockers
ACEI/ARB
Calcium channel blockers
Aspirin
Statin
Resting heart rate (bpm)
Elevated Heart rate ≥75bpm

Multivariable Modelc

B [95% CI]

P-value

B [95% CI]

P-value

0.01 [0.01 to 0.01]
0.09 [0.03 to 0.14]
0.01 [-0.014 to 0.001]
0.001 [-0.051 to 0.049]
0.15 [0.09 to 0.20]
0 [-0.05 to 0.05]
0.13 [0.08 to 0.18]
0.04 [-0.01 to 0.09]
0.003 [0.002 to 0.004]
0.002 [-0.005 to 0.000]
0.001 [-0.036 to 0.034]
0.06 [-0.13 to 0.02]
0.02 [-0.04 to 0.01]
0.02 [-0.03 to 0.00]
0.002 [-0.02 to 0.02]
0.004 [0.001 to 0.007]
0.001 [0.000 to 0.002]

<0.001*
0.001*
0.079
0.96
<0.001*
1.0
<0.001*
0.14
<0.001*
0.09
0.94
0.13
0.21
0.017*
0.84
0.007*
0.001*

0.006 [0.003 to 0.008]
0.05 [-0.02 to 0.12]
0.003 [-0.01 to 0.01]

<0.001*
0.15
0.41

0.11 [0.06 to 0.17]

<0.001*

0.07 [0.02 to 0.13]

0.010*

0.003 [0.001 to 0.005]
0.005 [-0.01 to 0.00]

0.003*
0.003*

0.002 [-0.01 to 0.01]

0.70

0.002 [0.000 to 0.005]
0.0 [-0.001 to 0.001]

0.07
0.69

0.03 [-0.02 to 0.08]
0.10 [0.05 to 0.15]
0.07 [0.01 to 0.12]
0.09 [0.03 to 0.14]
0.03 [-0.09 to 0.02]
0.004 [0.002 to 0.006]
0.11 [0.05 to 0.17]

0.26
<0.001*
0.017*
0.003*
0.20
<0.001*
<0.001*

0.05 [-0.001 to 0.10]
0.05 [0.00 to 0.11]
0.01 [-0.05 to 0.07]

0.06
0.07
0.66

0.002 [-0.001 to 0.004]
0.05 [-0.02 to 0.12]

0.14
0.16

Abbreviations: BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, glycosylated haemoglobin A1c;
hs-CRP, high-sensitivity C-reactive protein; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
*P < 0.05.
a
Absolute change estimates and 95% conﬁdence interval of unstandardized B estimate of carotid IMT explained by variable of interest
as estimated by univariable and multivariable Cox proportional hazards regression model.
b
Crude unadjusted model.
c
Adjusted for potential confounders as deﬁned as from univariable analysis with p-value 0.10.

lost in this group of high-risk CV patients
(R ¼ 0.03, P ¼ 0.46). HR-PR interval dissociation
was signiﬁcantly associated with HbA1c > 7 (28%
[HbA1c > 7] versus 17% [HbA1c  7], P ¼ 0.006). In
multivariable analyses, adjusted for potential confounders (age, gender, history of coronary artery
disease, ischemic stroke, systolic and diastolic blood
pressure, use of CV medications, physical activity,
BMI), HR-PR interval dissociation remained independently associated with HbA1c > 7 (OR ¼ 2.01
[95%CI 1.23e3.28], P ¼ 0.005).

Discussion
Resting HR is a strong positive predictor for coronary artery disease, HF, sudden cardiac death, and
all-cause mortality across different populations
[13e17]. In cardiac patients who undergo percutaneous coronary intervention, increased resting HR is
also a predictor for 30-day adverse CV outcomes
[18]. Our study here further demonstrated that
higher resting HR, either as a continuous

measurement or at cut-off of 75bpm, is an independent predictor for incident HF in patients with
CV diseases, or risk equivalent. We further showed
that averaged glycemic level in the immediate past 3
months prior to assessment, as measured by HbA1c,
was independently associated with increased resting
HR in this population. Interestingly, HR-PR interval
dissociation, a novel marker of cardiac autonomic
dysfunction proposed by us, is also independently
associated with HbA1c. Taken together, we
described markers that suggest presence of cardiac
autonomic dysfunction in this sample with prevalent
DM (51%) that correlated with worse chronic glycemic levels, and has prognostic implications on clinical sequalae in terms of incident HF.
Our ﬁndings are coherent with prior literature. An
earlier study of 594 diabetic patients showed that
resting tachycardia at a rate dichotomized at >100
bpm was independently associated with myocardial
infarction or stroke, and long-term mortality [19]. In
a follow-up analysis of the Framingham Heart
Study, orthostatic hypotension, another marker of
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Table 4. Predictors for brachial-ankle pulse wave velocity (PWV)a.
Univariable Modelb

Age (years)
Male
Body mass index (kgm2)
Coronary Artery Disease
Prior stroke
Diabetes mellitus d
Current/Past smoker
Regular Physical activity
Systolic BP (mmHg)
Diastolic BP (mmHg)
LDL-cholesterol (mmol/L)
HDL-cholesterol (mmol/L)
Triglycerides (mmol/L)
Fasting glucose (mmol/L)d
HbA1c (%)d
hs-CRP (mg/L)
Serum creatinine (mmol/L)
Medications:
Beta-blockers
ACEI/ARB
Calcium channel blockers
Aspirin
Statin
Resting heart rate (bpm)
Elevated Heart rate 75bpm

Multivariable Modelc

B [95% CI]

P-value

B [95% CI]

P-value

12.34 [9.28 to 15.41]
103.30 [-184.66 to 21.95]
4.46 [-15.89 to 6.97]
101.40 [-176.66 to 26.15]
128.5 [44.83 to 212.17]
126.25 [53.78 to 198.72]
36.12 [-109.74 to 37.49]
73.29 [-4.25 to 150.84]
9.10 [7.43 to 10.78]
6.67 [2.89 to 10.46]
14.40 [-37.91 to 66.70]
90.80 [-201.44 to 19.84]
23.59 [-11.55 to 58.74]
35.18 [17.26 to 53.11]
58.40 [33.39 to 83.41]
2.34 [-1.86 to 6.53]
0.55 [-0.44 to 1.54]

<0.001*
0.013*
0.44
0.008*
0.003*
0.001*
0.34
0.06
<0.001*
0.001*
0.59
0.11
0.19
<0.001*
<0.001*
0.27
0.27

12.02 [8.28 to 15.76]
45.07 [-123.48 to 33.34]

<0.001*
0.26

20.83 [-127.85 to 86.19]
120.08 [25.53 to 214.63]

0.70
0.013*

19.44 [-58.47 to 97.35]
5.75 [2.75 to 8.75]
2.57 [-2.48 to 7.62]

0.62
<0.001*
0.32

45.39 [22.13 to 68.66]

<0.001*

26.69 [-47.06 to 100.43]
16.15 [-58.78 to 91.07]
105.57 [24.00 to 187.13]
37.37 [-124.82 to 50.08]
63.88 [-140.61 to 12.85]
8.37 [5.88 to 10.85]
193.34 [100.65 to 286.04]

0.48
0.67
0.011*
0.40
0.10
<0.001*
<0.001

33.94 [-113.81 to 45.92]

0.40

27.88 [-119.00 to 63.25]
0.37 [-2.62 to 3.36]
1.25 [-95.47 to 92.97]

0.55
0.81
0.98

Abbreviations: BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, glycosylated haemoglobin A1c;
hs-CRP, high-sensitivity C-reactive protein; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
*P < 0.05.
a
Absolute change estimates and 95% conﬁdence interval of unstandardized B estimate of brachial-ankle PWV explained by variable of
interest as estimated by univariable and multivariable Cox proportional hazards regression model.
b
Crude unadjusted model.
c
Adjusted for potential confounders as deﬁned as from univariable analysis with p-value 0.10.
d
Related variables; only HbA1c was entered into the multivariable model to avoid collinearity.

autonomic dysfunction, was associated with incident HF over a median period of 13 years [20].
Diabetic patients with orthostatic hypotension, a
feature of autonomic dysfunction, suffers from
increased mortality and circadian rhythm alterations [21]. Elevated HbA1c level is associated with
blunted autonomic response in terms of HR variability [22]. Similar alterations in terms of HR variability and HR turbulence were seen in impaired
fasting glucose subjects [23].
DM is closely linked to development of HF.
Prevalence of DM is higher amongst patients hospitalized with worsening HF, compared to those
with chronic HF. Although pathophysioloogical
basis of diabetic cardiomyopathy is not yet fully
understood, autonomic dysfunction played an
important role alongside with other key elements of
microvascular dysfunction, oxidative stress, reninangiotensin system activation, and metabolic dysregulations [24e26]. Metabolic and neurohormonal
abnormalities may contribute to worsened

outcomes in patients with concomitant DM and HF
[27]. A study of 1402 patients with type 1 diabetes
investigated longitudinal changes of HR over 22
years. It was shown that higher HR predicted the
composite endpoint of CV events comprising coronary events, revascularization, nonfatal stroke,
congestive HF and CV death, independent of other
risk factors. Furthermore, patients who underwent
intensive glycemic control and signiﬁcantly lower
HR compared to those with conventional treatment,
and that treatment group differences in HR were
explained by HbA1c level [28]. These ﬁndings, in
conjunction with ours, highlights that poor glycemic
control is reﬂected as cardiac autonomic dysfunction, which in turn negatively impacts on subsequent CV and HF risk, thus supporting the need for
early glycemic control.
In our analyses, although there are positive associations between resting HR and carotid IMT, as
well as PWV, they were statistically insigniﬁcant
after adjustment for potential confounders. These
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suggest that elevation of resting HR impact on the
risk of HF via mechanistic pathways other than
atherosclerotic progression. Nevertheless, data on
this aspect are variable. Another study in a population-based cohort showed that resting HR was
associated with carotid atherosclerosis [29]. Another
study amongst asymptomatic Korean subjects
showed that resting HR was positively associated
with coronary calcium score [30]. Whether such
discrepancies of ﬁndings were due to different
subject risk proﬁles needs to be further investigated
in future studies.
PR interval normally exhibit an inverse relation
with resting HR [31], but such a relation is lost in
this our high-risk group of subjects with high
prevalence of DM. Our description of the HR-PR
interval dissociation and its relations with HbA1c is
novel. PR interval, a reﬂection of atrioventricular
conduction and at least partially a marker of vagal
tone especially in the young, received increasing
attention in recent years as a risk indicator of CV
risk. Prolongation of PR interval is associated with
increased risk of atrial ﬁbrillation, pacemaker implantation and all-cause mortality [32]. Its presence
also predicted adverse vascular function or
increased risk of composite CV events across
various levels of the CV continuum [7,9,33,34]. The
role or applicability of HR-PR interval dissociation
as a marker of cardiac autonomic dysfunction
should be further explored in future studies.
This study has several limitations. Firstly, it is an
observational study that is inherently subject to
various biases and residual confounding. Nevertheless, meticulous adjustment for potential confounders were made in the multivariable
analytical model. Furthermore, although we tested
for any potentially confounding effect of betablocker use in relation to resting HR, another
important clinical variable to consider is thyroid
function status. Assessment for thyroid function is
not available in this cohort, and should be
considered carefully in the interpretation. Secondly, the cohort has a relatively small sample
size, and is limited to the Chinese ethnicity.
Whether the ﬁndings may be extrapolated to other
populations should be tested in larger, multiethnic cohorts. Furthermore, other measures of
cardiac autonomic dysfunction, such as commonly
HR variability, HR turbulence and recovery, and
QT-RR slope, were not available. Therefore, no
established
marker
of cardiac autonomic
dysfunction was used to correlate with or validate
the role of HR-PR interval dissociation. In addition, only a single measurement of HR and PR
interval was available, rendering complex

relations between HR and PR interval in each individual unclear. Similarly, the chronicity of hyperglycemia was determined by an averaged
estimate over 3 months by a single measurement
of HbA1c, and repeated interval measurements
were not available. Thus, the ﬁndings of this study
on the proposed marker of HR-PR interval dissociation and its adopted values of speciﬁc cut-offs
should be regarded as exploratory. These should
be further investigated and conﬁrmed in further
studies.

Conclusions
We conclude that chronic hyperglycemia is associated with increased HR and counter-physiological
dissociation of resting HR and PR interval, and that
such increased HR predicts new-onset HF. The potential role of cardiac autonomic dysfunction as an
explanatory mechanism for HF should be further
investigated in future studies.
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